I van Asten1,2, R E G Schutgens1,2, M Baaij3,1,2, J Zandstra3, M Roest3, G Pasterkamp3, A Huisman3, S J A Korporaal3, R T Urbanus3. 1. Van Creveld Laboratory, University Medical Center Utrecht, Utrecht, the Netherlands. 2. Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands. 3. Department of Clinical Chemistry and Haematology, Center for Circulatory Health, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Abstract
Essentials The diagnosis of mild platelet function disorders (PFDs) is challenging. Validation of flow cytometric testing in patients with suspected PFDs is required. Flow cytometry has added value to light transmission aggregometry (LTA) in diagnosis of PFDs. There is fair agreement in diagnosing PFDs between LTA and flow cytometry. SUMMARY: Background Light transmission aggregometry (LTA) is the most commonly used test for the diagnosis of platelet function disorders (PFDs), but has moderate sensitivity for mild PFDs. Flow cytometry has been recommended for additional diagnostics of PFDs but is not yet standardized as a diagnostic test. We developed a standardized protocol for flow cytometric analysis of platelet function that measures fibrinogen binding and P-selectin expression as platelet activation markers in response to agonist stimulation. Objectives To determine the additional value of flow cytometric platelet function testing to standard LTA screening in a cross-sectional cohort of patients with a suspected PFD. Methods Platelet function was assessed with flow cytometry and LTA in 107 patients suspected of a PFD in whom von Willebrand disease and coagulation factor deficiencies were excluded. Both tests were compared in terms of agreement and discriminative ability for diagnosing patients with PFDs. Results Out of 107 patients, 51 patients had an elevated bleeding score; 62.7% of the patients had abnormal platelet function measured with flow cytometry and 54.2% of the patients were abnormal based on LTA. There was fair agreement between LTA and flow cytometry (κ = 0.32). The discriminative ability of flow cytometric analysis in patients with an elevated bleeding score was good (AUC 0.82, 0.74-0.90), but moderate for LTA (AUC 0.70, 0.60-0.80). Both tests combined had a better discriminative ability (AUC 0.87, 0.80-0.94). Conclusion Flow cytometric analysis of platelet function has added value in diagnostics of PFDs in patients with unexplained bleeding tendency.
Essentials The diagnosis of mild platelet function disorders (PFDs) is challenging. Validation of flow cytometric testing in patients with suspected PFDs is required. Flow cytometry has added value to light transmission aggregometry (LTA) in diagnosis of PFDs. There is fair agreement in diagnosing PFDs between LTA and flow cytometry. SUMMARY: Background Light transmission aggregometry (LTA) is the most commonly used test for the diagnosis of platelet function disorders (PFDs), but has moderate sensitivity for mild PFDs. Flow cytometry has been recommended for additional diagnostics of PFDs but is not yet standardized as a diagnostic test. We developed a standardized protocol for flow cytometric analysis of platelet function that measures fibrinogen binding and P-selectin expression as platelet activation markers in response to agonist stimulation. Objectives To determine the additional value of flow cytometric platelet function testing to standard LTA screening in a cross-sectional cohort of patients with a suspected PFD. Methods Platelet function was assessed with flow cytometry and LTA in 107 patients suspected of a PFD in whom von Willebrand disease and coagulation factor deficiencies were excluded. Both tests were compared in terms of agreement and discriminative ability for diagnosing patients with PFDs. Results Out of 107 patients, 51 patients had an elevated bleeding score; 62.7% of the patients had abnormal platelet function measured with flow cytometry and 54.2% of the patients were abnormal based on LTA. There was fair agreement between LTA and flow cytometry (κ = 0.32). The discriminative ability of flow cytometric analysis in patients with an elevated bleeding score was good (AUC 0.82, 0.74-0.90), but moderate for LTA (AUC 0.70, 0.60-0.80). Both tests combined had a better discriminative ability (AUC 0.87, 0.80-0.94). Conclusion Flow cytometric analysis of platelet function has added value in diagnostics of PFDs in patients with unexplained bleeding tendency.
Authors: Farahnaz Waissi; Mirthe Dekker; Ingrid E M Bank; Suzanne J A Korporaal; Rolf T Urbanus; Gert J de Borst; Gerard Pasterkamp; Asbjorn M Scholtens; Diederick E Grobbee; Arend Mosterd; Dominique P V de Kleijn; Leo Timmers Journal: Res Pract Thromb Haemost Date: 2020-05-15
Authors: Verónica Palma-Barqueros; Nuria Revilla; Ana Sánchez; Ana Zamora Cánovas; Agustín Rodriguez-Alén; Ana Marín-Quílez; José Ramón González-Porras; Vicente Vicente; María Luisa Lozano; José María Bastida; José Rivera Journal: Int J Mol Sci Date: 2021-04-26 Impact factor: 5.923
Authors: Lisa N van der Vorm; Li Li; Dana Huskens; Walid Chayouâ; Hilde Kelchtermans; Philip G de Groot; Mark Roest; Jasper A Remijn; Bas de Laat Journal: PLoS One Date: 2019-02-13 Impact factor: 3.240
Authors: Ivar van Asten; Maaike Blaauwgeers; Lianne Granneman; Harry F G Heijnen; Marieke J H A Kruip; Erik A M Beckers; Michiel Coppens; Jeroen Eikenboom; Rienk Y J Tamminga; Gerard Pasterkamp; Albert Huisman; Karin P M van Galen; Suzanne J A Korporaal; Roger E G Schutgens; Rolf T Urbanus Journal: J Thromb Haemost Date: 2019-12-27 Impact factor: 5.824
Authors: Tessa Noordermeer; Ivar van Asten; Roger E G Schutgens; Anke J Lakerveld; Cornelis A Koekman; Kay Y Hage; Silvie A E Sebastian; Albert Huisman; Dave J van den Heuvel; Hans C Gerritsen; Suzanne J A Korporaal; Marc Bierings; Jasper J van der Smagt; Mariëlle E van Gijn; Rolf T Urbanus Journal: Blood Adv Date: 2022-06-14
Authors: Marjon H Cnossen; Iris van Moort; Simone H Reitsma; Moniek P M de Maat; Roger E G Schutgens; Rolf T Urbanus; Hester F Lingsma; Ron A A Mathot; Samantha C Gouw; Karina Meijer; Annelien L Bredenoord; Rieke van der Graaf; Karin Fijnvandraat; Alexander B Meijer; Emile van den Akker; Ruben Bierings; Jeroen C J Eikenboom; Maartje van den Biggelaar; Masja de Haas; Jan Voorberg; Frank W G Leebeek Journal: J Thromb Haemost Date: 2022-06-02 Impact factor: 16.036